Results 1 to 10 of about 18,252,794 (250)

Racial disparities in breast cancer treatment patterns and treatment related adverse events. [PDF]

Sci Rep, 2023
The main objective of this work was to perform a comprehensive analysis and provide a race-stratified epidemiological report accounting for differences in treatment patterns and treatment related adverse events in Non-Hispanic women with breast cancer ...
Stabellini N, Cullen J, Cao L, Shanahan J, Hamerschlak N, Waite K, Barnholtz-Sloan JS, Montero AJ.   +7 more
europepmc   +2 more sources

Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. [PDF]

Front Oncol, 2021
Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small ...
O'Brien SM, Brown JR, Byrd JC, Furman RR, Ghia P, Sharman JP, Wierda WG.   +6 more
europepmc   +2 more sources

Sleep Disturbance, Treatment-Related Adverse Events, and Psychological Distress in Breast Cancer Patients: A Prospective Cohort Study. [PDF]

Patient Prefer Adherence
Fang Zhao,1,* Yuqiu Li,1,* Yanjun Zhou,2 Enfeng Fu,1 Shanshan Zhu,1 Lulu Yu,1 Hangcheng Xu,1 Qing Li,1 Qiao Li,1 Pin Zhang,1 Jiani Wang,1 Hongnan Mo1 1Department of Medical Oncology, National Cancer Center/National Clinical Research ...
Zhao F, Li Y, Zhou Y, Fu E, Zhu S, Yu L, Xu H, Li Q, Li Q, Zhang P, Wang J, Mo H.   +11 more
europepmc   +2 more sources

Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis. [PDF]

Front Oncol
AimThis study comprehensively assesses the incidence and profiles of treatment-related adverse events (trAEs) of immune checkpoint inhibitor (ICI)-based therapies across cancer at various sites.MethodsWe systematically searched the PubMed, Embase, and ...
Shen X, Yang J, Qian G, Sheng M, Wang Y, Li G, Yan J.   +6 more
europepmc   +2 more sources

Miscarriage treatment-related adverse events: A nationwide registry study from Finland. [PDF]

Acta Obstet Gynecol Scand
Introduction The treatment of miscarriage has transformed substantially from surgical to non‐surgical. The aim of this study was to evaluate the rates of adverse events related to the treatment of miscarriage and their risk factors.
Helle N, Mentula M, Seppälä T, Gissler M, Niinimäki M, Heikinheimo O.   +5 more
europepmc   +2 more sources

Treatment-related adverse events of antibody drug-conjugates in clinical trials. [PDF]

J Hematol Oncol
Background Antibody–drug conjugates (ADCs) aim to enhance the therapeutic index of cytotoxic agents but can cause unexpected toxicities. This study evaluated adverse events (AEs) from phase 1 trials at The Royal Marsden Drug Development Unit (DDU) over a
Tan HN, Morcillo MA, Lopez J, Minchom A, Sharp A, Paschalis A, Silva-Fortes G, Raobaikady B, Banerji U.   +8 more
europepmc   +2 more sources

Home-Based Monitoring of Treatment-Related Adverse Events during Drug-Resistant Tuberculosis Treatment, India, 2020-2024. [PDF]

Emerg Infect Dis
We investigated home-based outreach and point-of-care diagnostic tools for monitoring adverse events among persons treated for drug-resistant tuberculosis in Dharavi, India.
Ahson M, Shah D, Bhide S, Deshmukh R, Smith JP, Waghmare S, Kaipilyawar S, Puri V, Khetade DK, Yeldandi V, Date A, Moonan PK, Ho CS.   +12 more
europepmc   +2 more sources

Treatment-related adverse events and response rate to immune checkpoint inhibition. [PDF]

J Int Med Res, 2020
Background Immune checkpoint inhibition (ICI) represents a novel treatment modality for refractory cancers, and improving prediction of potential responders is critical. Method We hypothesized that ICI is a systemic-effecting mechanism.
Li Y, Wang Z, Guo T, Liu S, Feng C.
europepmc   +2 more sources

Treatment strategies and treatment-related adverse events in MG according to the age of onset. [PDF]

Front Neurol
IntroductionEarly-onset (EOMG) and late-onset (LOMG) are distinct groups of MG patients. It is unclear if treatment strategies and treatment-related adverse events may differ according to the age of MG onset.MethodsThis single-center retrospective study ...
Moura J, Fernandes J, Lima MJ, Sousa AP, Samões R, Martins Silva A, Santos E.   +6 more
europepmc   +2 more sources

Prior Immune Checkpoint Inhibitor Treatment Is a Risk Factor for Treatment-Related Adverse Events in Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab. [PDF]

JGH Open
Aims In March 2024, the American Society of Clinical Oncology recommended the combination of tremelimumab plus durvalumab as a treatment for advanced hepatocellular carcinoma (HCC).
Watanabe N, Kobayashi T, Iwaki M, Nogami A, Wada N, Shimizu A, Komori T, Koike H, Sahashi Y, Nakajima A, Yoneda M.   +10 more
europepmc   +2 more sources